GLP-1 Medications: Who Should Use Them?

Key Takeaways

GLP-1 receptor agonists are approved for specific conditions such as obesity and type 2 diabetes, and eligibility depends on individual health history.
Research suggests potential benefits beyond weight loss, including cardiovascular and pain-related effects, but evidence is still evolving.
Certain populations—including older adults and people with epilepsy—require extra clinical consideration before starting GLP-1 therapy.
Rare but serious safety signals, such as a reported eye condition called NAION, highlight the importance of ongoing monitoring by a healthcare provider.
Weight regain after stopping GLP-1 medications is a documented concern, making long-term treatment planning a key part of the conversation with your doctor.

What are GLP-1 medications and how do they work?

GLP-1 medications are a class of drugs that mimic a natural hormone your body already makes, helping to regulate blood sugar, slow digestion, and reduce appetite — effects that together can support meaningful weight loss. They don’t work like older diet pills that simply suppress hunger through stimulants; they work with your body’s own signaling systems.

The hormone they copy

GLP-1 stands for glucagon-like peptide-1 — a hormone your gut releases after you eat. Think of it as a messenger that tells your brain you’re full, tells your pancreas to release insulin, and tells your stomach to empty more slowly. GLP-1 receptor agonists (the formal name for this drug class — “agonist” just means “activator”) are engineered molecules that bind to the same receptors that natural GLP-1 targets, but they stay active in your body far longer than the hormone your gut produces on its own.

What they actually do, step by step

Slow stomach emptying. Food moves from your stomach to your intestines more gradually, so you feel full longer after a meal.
Signal fullness to the brain. These medications act on appetite-regulating areas of the brain, reducing hunger between meals.
Improve blood sugar control. They prompt the pancreas to release insulin when blood sugar rises, which matters especially for people with type 2 diabetes — though many people use them for weight management alone.
Reduce calorie intake over time. Because hunger signals quiet down, most people naturally eat less without rigid calorie counting.

A 2025 state-of-the-art review describes GLP-1 receptor agonists as acting on multiple organ systems simultaneously — the gut, the pancreas, the brain, and the cardiovascular system — which helps explain why their effects extend beyond weight loss alone.

The medications in this class

Several GLP-1 medications are currently available or in use. Some target only the GLP-1 receptor (like semaglutide). Others, like tirzepatide, activate a second receptor called GIP as well, making them dual agonists. A 2025 review focused on older adults notes that GLP-1 receptor agonists vary in their dosing schedules, delivery methods, and side-effect profiles — differences that matter when you and your doctor choose the right fit for you.

Results vary from person to person. Weight loss is real and documented, but it is not guaranteed, and these medications work best alongside lifestyle changes.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Who are GLP-1 medications typically prescribed for?

GLP-1 medications are typically prescribed for adults with obesity (a BMI of 30 or higher) or for adults who are overweight (a BMI of 27 or higher) and have at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol. Doctors use these thresholds as a starting point, but the full picture is more nuanced.

The core eligibility criteria

BMI of 30 or higher — This meets the clinical definition of obesity on its own.
BMI of 27–29.9 with a related health condition — The extra weight is actively affecting your health, which shifts the risk-benefit calculation in favor of treatment.
Type 2 diabetes — GLP-1 medications were originally developed to lower blood sugar, and many people with type 2 diabetes still receive them for that purpose alongside weight management, as this cardiovascular review outlines.

BMI is a blunt tool. It measures weight relative to height but says nothing about where fat sits in the body or how it affects your organs. Your doctor will look at the whole picture.

Conditions that often factor into the decision

Weight-related joint pain is one example. Carrying extra weight puts mechanical stress on the spine and knees, and this pain medicine review discusses how GLP-1 therapies are being evaluated in that context. Heart health is another—research on incretin-based therapies shows that GLP-1 medications can reduce the risk of serious cardiovascular events in people who already have heart disease.

Age and other individual factors

Older adults represent a growing group of GLP-1 users. A reappraisal of GLP-1 use in older adults notes that prescribing decisions in this group require extra attention to muscle loss and frailty—factors that don’t show up in a BMI number. People with certain other conditions, such as epilepsy, may also be candidates; one study examined safety and effectiveness specifically in adults managing both epilepsy and obesity.

What this means practically

No single number makes you automatically eligible or ineligible. A prescriber weighs your BMI, your existing health conditions, your medication history, and your personal goals together. Real-world prescribing patterns confirm that use is expanding across a wide range of patients, as this utilization study from Croatia illustrates.

Are there groups who need extra caution before starting?

Yes, some groups need extra caution — and in certain cases, a full conversation with their doctor — before starting a GLP-1 medication. These aren’t reasons to rule out treatment automatically, but they are reasons to slow down and get personalized guidance.

People who may need extra care include:

Older adults (roughly 65 and up). GLP-1 medications cause nausea, reduced appetite, and weight loss that includes muscle mass — effects that hit harder as people age. A reappraisal of GLP-1s in older adults highlights that older patients face a higher risk of losing muscle alongside fat, which can affect strength, balance, and independence. A doctor can help build in strategies — like protein targets and resistance exercise — to protect muscle during treatment.
People with epilepsy. This surprises many people. GLP-1 medications interact with anti-seizure drugs by changing how the body absorbs them, which may shift medication levels in the blood. A safety study of GLP-1s in adults with epilepsy, obesity, and type 2 diabetes (source) found that while these medications can be used in this group, careful monitoring of seizure control and drug levels is essential.
People with a history of certain eye conditions. A rare but serious concern. One published case report documented sudden vision loss in one eye — a condition called non-arteritic anterior ischemic optic neuropathy (NAION), meaning a sudden loss of blood flow to the optic nerve — following tirzepatide use. That case report doesn’t prove the drug caused the event, but anyone with pre-existing eye or optic nerve disease should flag this with both their prescriber and their eye doctor before starting.
People with existing heart or blood vessel conditions. GLP-1 medications have shown cardiovascular benefits in many people, but the picture is nuanced. A state-of-the-art review of incretins as cardiovascular agents makes clear that individual cardiovascular history matters when selecting a medication and monitoring its effects.
People with skin conditions under active dermatology care. GLP-1 medications affect skin-related inflammation in ways that interact with existing treatments. A guide on integrating GLP-1s into dermatology practice recommends that dermatologists and prescribers coordinate care when a patient is managing both.

None of these groups are automatically excluded. Extra caution means extra conversation — not a closed door.

This content is for general informational purposes only and is not medical advice. It does not replace the guidance of a qualified healthcare professional. Always consult your doctor, pharmacist, or other licensed provider before starting, stopping, or changing any medication or treatment.

What safety signals should patients and doctors watch for?

GLP-1 medications carry a well-documented set of safety signals that both patients and their doctors should actively monitor — ranging from common digestive side effects to rarer but serious concerns involving vision, muscle loss, and heart rhythm. Knowing what to watch for helps you act quickly when something needs attention.

Common signals to track from the start

Most people starting a GLP-1 medication notice digestive changes first. Nausea, vomiting, diarrhea, and constipation are the most frequently reported side effects, and they tend to peak early in treatment, especially after a dose increase. These are uncomfortable but usually manageable. Your care team can adjust your dose or timing to help.

Appetite suppression is the intended effect — but it can go too far. Eating too little protein and calories can cause your body to break down muscle alongside fat. A review on older adults flags muscle loss (called sarcopenia — a gradual loss of muscle mass and strength) as a meaningful concern, particularly for people over 60. Tell your doctor if you feel unusually weak or if your activity level drops significantly.

Signals that need prompt medical attention

Some warning signs require a same-day or emergency call to your provider:

Sudden vision changes. A published case report documents a patient who developed acute vision loss in one eye — a condition called NAION (non-arteritic anterior ischemic optic neuropathy, meaning the optic nerve loses blood supply suddenly) — after starting tirzepatide. Any sudden blurring, loss of vision, or visual disturbance warrants immediate evaluation.
Severe abdominal pain. Pancreatitis (inflammation of the pancreas) is a known risk. Persistent, severe pain in the upper abdomen — especially pain that radiates to the back — is a red flag.
Heart rhythm changes. Cardiovascular research shows GLP-1 drugs affect heart rate and rhythm. Report palpitations, racing heartbeat, or dizziness to your doctor.
Seizure changes. People with epilepsy face a specific monitoring need. A safety study in adults with epilepsy, obesity, and type 2 diabetes (source) found that GLP-1 medications can alter how the body absorbs anti-seizure drugs, potentially changing seizure control.

Skin and dermatology signals

Hair thinning after rapid weight loss is common and usually temporary. Dermatology monitoring guidance recommends watching for new or worsening skin conditions, since immune and inflammatory pathways shift during significant weight change.

After stopping the medication

Weight regain after stopping is real and well-documented. A prospective Japanese study tracked patients after treatment ended and found meaningful regain without ongoing lifestyle support. That is not a failure — it is biology. Plan for it with your care team before you stop.

This content is for general informational purposes only and is not medical advice. It does not replace consultation with a qualified healthcare professional. Never start, stop, or change a medication based on information you read here.

What happens if you stop taking a GLP-1 medication?

Most people who stop taking a GLP-1 medication regain a significant portion of the weight they lost — often within months. The medication doesn’t permanently change how your body regulates hunger and fat storage, so those processes tend to return to their pre-treatment patterns once the drug leaves your system.

Why weight comes back

GLP-1 medications work by mimicking a natural hormone (called glucagon-like peptide-1) that helps control appetite and blood sugar. While you’re taking the medication, it signals your brain to feel fuller sooner and slows the rate at which your stomach empties. Stop the medication, and those signals stop too.

A real-world study conducted in Japan found that patients who discontinued GLP-1 therapy experienced meaningful weight regain after stopping, reinforcing that the medication’s effects depend on continued use rather than a one-time reset of the body’s set point — Japanese real-world study.

What the pattern typically looks like

Weight regain often begins within weeks of stopping and can accelerate over the following months.
Hunger levels and food cravings tend to return toward baseline as the drug clears the body.
Any improvements in blood sugar control linked to weight loss may reverse, depending on your underlying health.
Cardiovascular benefits associated with GLP-1 use — such as improvements in blood pressure and lipid levels — may diminish as weight returns, since many of those gains are partly weight-dependent, incretin cardiovascular review.

This doesn’t mean stopping is always wrong

Some people stop intentionally — because of side effects, cost, pregnancy planning, or a personal decision made with their care team. Others stop because of supply issues or insurance changes. Whatever the reason, stopping abruptly is generally considered safe from a physical standpoint; GLP-1 medications don’t cause dependence or withdrawal symptoms in the clinical sense.

Regain is not a personal failure. It reflects how these medications work biologically.

What you can do

Talk to your prescriber before stopping if you can. They may suggest a tapering plan, a transition to lifestyle strategies, or a different medication. Research into long-term management after GLP-1 discontinuation is still evolving, and a clinician familiar with your full health picture is the right person to help you plan — reappraisal in older adults.

How do you start the conversation with your healthcare provider?

Come prepared with a clear, honest summary of your health history, your goals, and any questions written down before your appointment. That preparation helps your provider give you the most relevant guidance in the time you have together.

Before your appointment, gather this information:

Your current weight and any previous weight-loss attempts (diets, programs, medications)
A list of every medication, supplement, or herbal product you take — GLP-1 medications can interact with other drugs, and your provider needs the full picture
Any diagnoses you currently manage, including heart disease, kidney disease, thyroid conditions, a history of pancreatitis, or epilepsy — research shows that people with epilepsy who take GLP-1 medications alongside seizure drugs need careful monitoring because of how these medicines are processed by the body (PMID 42563258)
Your age and any concerns specific to it — older adults face distinct considerations with these medications, including the risk of losing muscle mass along with fat, which makes the conversation about monitoring even more important (PMID 42567819)

Questions worth asking out loud:

“Am I a good candidate for a GLP-1 medication, and why or why not?”
“What side effects should I watch for, and when should I call you?”
“Are there any rare but serious risks I should know about?” — for example, a small number of case reports have described sudden vision changes in people using these medications, which is worth raising if you have any eye conditions (PMID 42569780)
“What does success look like, and how will we track it together?”
“What happens if I need to stop the medication?”

Be direct about your lifestyle. Research following people on GLP-1 therapy found that weight tends to return after stopping the medication without ongoing lifestyle support, so your provider needs to know what your daily eating and activity habits actually look like — not what you think they want to hear (PMID 42552238).

Honesty matters more than a polished answer. Your provider is not there to judge your history. They need accurate information to make a safe plan with you.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health or any medication.

FAQ

Can GLP-1 medications help with pain, not just weight?

Early research suggests GLP-1 receptor agonists may have benefits for obesity-related pain conditions such as low back and knee pain, possibly through weight reduction and anti-inflammatory effects. However, this area of research is still developing, and these medications are not currently approved specifically for pain management. Talk to your doctor about whether any potential pain-related benefits apply to your situation.

Are GLP-1 medications safe for older adults?

A published review notes that GLP-1 receptor agonists require careful reappraisal in older adults, as this group may face different risk-benefit considerations, including concerns about muscle loss, nutritional status, and other age-related factors. Older adults should have a thorough discussion with their healthcare provider before starting these medications.

Can people with epilepsy take GLP-1 medications?

Research on GLP-1 receptor agonists in adults with both epilepsy and obesity or type 2 diabetes is ongoing. A published study examined safety and efficacy in this population, but the findings are preliminary. Anyone with a seizure disorder should consult their neurologist and prescribing physician before considering GLP-1 therapy.

Is there a risk of eye problems with GLP-1 medications?

A published case report described a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) in a patient using tirzepatide, a dual GIP/GLP-1 receptor agonist. This is a rare event and a single case report cannot establish cause and effect, but it underscores the importance of reporting any sudden vision changes to a healthcare provider immediately.

Do GLP-1 medications have heart health benefits?

Research published in peer-reviewed journals indicates that incretin-based therapies, including GLP-1 receptor agonists, may offer cardiovascular benefits such as reductions in major adverse cardiac events in certain high-risk populations. However, individual cardiovascular risk profiles vary widely, and a cardiologist or primary care physician should guide any treatment decisions.

Published guidance on integrating GLP-1 receptor agonists into dermatology practice highlights that some patients may experience skin-related changes and that monitoring strategies are important. If you have a pre-existing skin condition or notice new skin symptoms after starting a GLP-1 medication, mention it to both your prescribing provider and a dermatologist.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.